JP2017530155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530155A5 JP2017530155A5 JP2017517713A JP2017517713A JP2017530155A5 JP 2017530155 A5 JP2017530155 A5 JP 2017530155A5 JP 2017517713 A JP2017517713 A JP 2017517713A JP 2017517713 A JP2017517713 A JP 2017517713A JP 2017530155 A5 JP2017530155 A5 JP 2017530155A5
- Authority
- JP
- Japan
- Prior art keywords
- methyloxy
- triazolo
- chlorophenyl
- methyl
- ethylacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 21
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 21
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 14
- 229940077388 benzenesulfonate Drugs 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 229940125763 bromodomain inhibitor Drugs 0.000 claims description 5
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002274 desiccant Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058753P | 2014-10-02 | 2014-10-02 | |
| US62/058,753 | 2014-10-02 | ||
| PCT/EP2015/072515 WO2016050821A1 (en) | 2014-10-02 | 2015-09-30 | Compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530155A JP2017530155A (ja) | 2017-10-12 |
| JP2017530155A5 true JP2017530155A5 (enExample) | 2018-01-11 |
Family
ID=54238438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517713A Pending JP2017530155A (ja) | 2014-10-02 | 2015-09-30 | 化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9975901B2 (enExample) |
| EP (1) | EP3201199A1 (enExample) |
| JP (1) | JP2017530155A (enExample) |
| KR (1) | KR20170055549A (enExample) |
| CN (1) | CN106715439A (enExample) |
| AU (1) | AU2015326910B2 (enExample) |
| BR (1) | BR112017006342A2 (enExample) |
| CA (1) | CA2960090A1 (enExample) |
| RU (1) | RU2697393C2 (enExample) |
| WO (1) | WO2016050821A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394449B (es) | 2012-01-12 | 2025-03-11 | Univ Yale | Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3. |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SG11201704089UA (en) | 2014-12-05 | 2017-06-29 | H Lee Moffitt Cancer Ct & Res | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| CA2979070A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2018086605A1 (zh) | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | 一种含氮大环类化合物、其制备方法、药物组合物及应用 |
| CN110612294B (zh) | 2017-01-31 | 2024-01-16 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| MX2020010571A (es) | 2018-04-13 | 2021-01-08 | Arvinas Operations Inc | Ligandos de cereblon y compuestos bifuncionales que los comprenden. |
| CN115175901B (zh) | 2019-12-19 | 2024-03-22 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0934940A1 (en) * | 1996-06-12 | 1999-08-11 | Japan Tobacco Inc. | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
| KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| DK2496582T3 (en) * | 2009-11-05 | 2016-03-21 | Glaxosmithkline Llc | Benzodiazepine-BROMDOMAeNEINHIBITOR. |
| PH12012500894A1 (en) * | 2009-11-05 | 2022-03-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB201106743D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| PT2773354T (pt) * | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
-
2015
- 2015-09-30 JP JP2017517713A patent/JP2017530155A/ja active Pending
- 2015-09-30 US US15/515,683 patent/US9975901B2/en not_active Expired - Fee Related
- 2015-09-30 RU RU2017107760A patent/RU2697393C2/ru active
- 2015-09-30 AU AU2015326910A patent/AU2015326910B2/en not_active Ceased
- 2015-09-30 KR KR1020177010949A patent/KR20170055549A/ko not_active Withdrawn
- 2015-09-30 CN CN201580053064.0A patent/CN106715439A/zh active Pending
- 2015-09-30 WO PCT/EP2015/072515 patent/WO2016050821A1/en not_active Ceased
- 2015-09-30 CA CA2960090A patent/CA2960090A1/en not_active Abandoned
- 2015-09-30 BR BR112017006342A patent/BR112017006342A2/pt not_active Application Discontinuation
- 2015-09-30 EP EP15771952.7A patent/EP3201199A1/en not_active Withdrawn
-
2018
- 2018-04-18 US US15/955,857 patent/US10450319B2/en not_active Expired - Fee Related
-
2019
- 2019-09-05 US US16/561,208 patent/US20190389870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530155A5 (enExample) | ||
| KR102011641B1 (ko) | 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형 | |
| RU2017107760A (ru) | Соединение | |
| JP2019524883A5 (enExample) | ||
| KR102150383B1 (ko) | 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법 | |
| JP2016512531A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2015532295A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| AU2015252007B2 (en) | Inhibiting the Transient Receptor Potential A1 ion channel | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| RU2015110699A (ru) | Фармацевтическая антиретровирусная композиция | |
| RU2019114940A (ru) | Лечение катаплексии | |
| JP7445597B2 (ja) | キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法 | |
| WO2013174930A3 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| RU2017114933A (ru) | Соединения и композиции для лечения или профилактики патологических состояний, связанных с избыточным отложением фибрина и/или образованием тромбов | |
| EP3006431B1 (en) | Tizoxanide carbamate and pharmaceutical use thereof | |
| JP2016510326A5 (enExample) | ||
| HRP20171511T1 (hr) | Ivabradin-hidroklorid, oblik iv | |
| US9221779B2 (en) | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity | |
| WO2015199234A1 (ja) | ハロゲン置換へテロ環化合物の塩 | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2015521191A5 (enExample) | ||
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2016514688A5 (enExample) |